Antibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations
- Flow cytometry [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 14-9217-80 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CD267 (TACI) Monoclonal Antibody (11H3), eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: The 11H3 antibody reacts with human TACI, also known as tumor necrosis factor receptor 13B. TACI, like BCMA, binds BAFF and April. TACI and its ligands regulate humoral immune responses, activate NF-kB and c-jun N-terminal kinase, and are involved in B cell associated autoimmune diseases. TACI mRNA and protein are found predominantly in B-cells and correlate with BLyS binding in a panel of B-cell lines. TACI interacts with nanomolar affinity with the BLyS-related tumor necrosis factor homologue APRIL for which no clear in vivo role has been described. 11H3 does not block binding of BAFF/BLyS to TACI.
- Antibody clone number
- 11H3
- Concentration
- 0.5 mg/mL
Submitted references TACI Isoforms Regulate Ligand Binding and Receptor Function.
Interferon-β therapy specifically reduces pathogenic memory B cells in multiple sclerosis patients by inducing a FAS-mediated apoptosis.
Differential induction of plasma cells by isoforms of human TACI.
Chemokine receptor expression and functional effects of chemokines on B cells: implication in the pathogenesis of rheumatoid arthritis.
Garcia-Carmona Y, Ting AT, Radigan L, Athuluri Divakar SK, Chavez J, Meffre E, Cerutti A, Cunningham-Rundles C
Frontiers in immunology 2018;9:2125
Frontiers in immunology 2018;9:2125
Interferon-β therapy specifically reduces pathogenic memory B cells in multiple sclerosis patients by inducing a FAS-mediated apoptosis.
Rizzo F, Giacomini E, Mechelli R, Buscarinu MC, Salvetti M, Severa M, Coccia EM
Immunology and cell biology 2016 Oct;94(9):886-894
Immunology and cell biology 2016 Oct;94(9):886-894
Differential induction of plasma cells by isoforms of human TACI.
Garcia-Carmona Y, Cols M, Ting AT, Radigan L, Yuk FJ, Zhang L, Cerutti A, Cunningham-Rundles C
Blood 2015 Mar 12;125(11):1749-58
Blood 2015 Mar 12;125(11):1749-58
Chemokine receptor expression and functional effects of chemokines on B cells: implication in the pathogenesis of rheumatoid arthritis.
Nanki T, Takada K, Komano Y, Morio T, Kanegane H, Nakajima A, Lipsky PE, Miyasaka N
Arthritis research & therapy 2009;11(5):R149
Arthritis research & therapy 2009;11(5):R149
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Staining of normal human peripheral blood cells with Anti-Human CD19 APC (Product # 17-0199-42) and 0.25 µg ofMouse IgG2a kappa Isotype Control Purified (Product # 14-4724-82) (left) or.025 µg of Anti-Human CD267 (TACI) Purified (right) followed by Anti-Mouse IgG Biotin (Product # 13-4013-85) and Streptavidin PE (Product # 12-4317-87). Cells in the lymphocyte gate were used for analysis.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- 5 IFN-beta-induced increase of TACI surface expression in memory B cells of MS patients. ( a ) Coexpression of TACI and FAS-R in CD27 + memory B cells was evaluated by FACS analysis in freshly isolated PBMCs of five RRMS patients sampled at baseline ( T 0), at T 1 (1 month) and T 6 (6 months) after IFN-beta therapy. Representative dot plots and cell frequencies are shown. ( b ) Levels of TACI expression evaluated in PBMCs of 10 RRMS at T 0 and T 1 in gated CD19 + total, CD19 + CD27 + memory and CD19 + CD27 - -naive B cells are depicted as scatter plots reporting all the obtained mean fluorescence intensity (MFI) values, together with medians. ** P 0.01; ***** P 0.00001.